
Meningococcal Vaccines Market Report and Forecast 2024-2032
Description
Meningococcal Vaccines Market Report and Forecast 2024-2032
The global meningococcal vaccines market was valued at USD 3.85172 bmillion doses in 20203. The market is expected to grow at a CAGR of 8.80% robust pace during the forecast period 2024-2032, driven by increasing awareness of the importance of vaccination, advancements in vaccine development, and rising demand for effective prevention of meningococcal diseases. The market is likely to reach a value of USD 8.23 billion by 2032.
Meningococcal Vaccines Market- Analysis
Meningococcal vaccines are critical immunisations used to prevent meningococcal infections, which can lead to severe conditions such as meningitis and septicaemia. These vaccines target different serotypes of Neisseria meningitidis, a bacterium responsible for life-threatening infections. The global meningococcal vaccines market has been growing steadily, driven by increased awareness of meningococcal disease, government immunisation programmes, and advancements in vaccine technology. As the demand for effective vaccines continues to rise, the market is poised for significant expansion over the forecast period.
Market Drivers
Increasing Awareness of Meningococcal Disease: Rising awareness of the severe consequences of meningococcal infections has led to increased demand for vaccines. Public health campaigns and educational initiatives are playing a crucial role in encouraging vaccination, particularly in high-risk populations.
Technological Advancements in Vaccine Development: The development of conjugate and combination vaccines has greatly improved the efficacy and safety of meningococcal vaccines. These advancements are making vaccines more effective across different age groups and serotypes, thereby expanding the market.
Growing Demand in Emerging Markets: Emerging markets, particularly in Asia and Africa, are experiencing a growing demand for meningococcal vaccines due to improved healthcare infrastructure, rising income levels, and increasing government focus on public health.
Market Challenges
Vaccine Hesitancy: Despite the proven efficacy of meningococcal vaccines, vaccine hesitancy remains a challenge. Misconceptions about vaccine safety and the spread of misinformation can hinder vaccination rates.
Limited Access in Low-Income Countries: Access to meningococcal vaccines is still limited in many low-income countries due to logistical challenges, insufficient healthcare infrastructure, and financial constraints. This limits the market potential in these regions.
Complex Regulatory Environment: The regulatory approval process for vaccines is complex and varies by region. Navigating these regulatory hurdles can be time-consuming and costly for manufacturers, delaying the introduction of new vaccines to the market.
Supply Chain Issues: Ensuring a consistent supply of vaccines can be challenging due to factors such as production complexities, cold chain requirements, and distribution logistics, particularly in remote or underserved areas.
Future Opportunities
Development of New Vaccines: There is ongoing research into developing vaccines that cover additional serotypes and offer broader protection. Companies investing in innovative vaccine development are likely to see significant market opportunities as these products reach the market.
Increased Focus on Adult Vaccination: While meningococcal vaccination is commonly associated with children and adolescents, there is growing recognition of the importance of vaccinating adults, particularly in high-risk groups. This presents an opportunity to expand the market.
Rising Demand for Combination Vaccines: The demand for combination vaccines that protect against multiple diseases, including meningococcal infections, is increasing. These vaccines offer convenience and improved compliance, driving their adoption in various immunisation programmes.
Meningococcal Vaccines Market Trends
Shift Towards Conjugate Vaccines: Conjugate vaccines, which offer longer-lasting immunity and are effective across all age groups, are becoming the standard in meningococcal vaccination. This trend is expected to continue as more countries adopt conjugate vaccines in their national immunisation schedules.
Increasing Use of Quadrivalent Vaccines: Quadrivalent vaccines that protect against four major serotypes (A, C, W-135, and Y) are gaining popularity due to their broad coverage. The preference for these vaccines is driving market growth, particularly in regions with diverse serotype prevalence.
Growing Adoption of Routine Vaccination: There is a global trend towards including meningococcal vaccines in routine immunisation schedules, particularly for infants and adolescents. This trend is being supported by increased funding and government initiatives, which are boosting market demand.
Rising Importance of Travel Vaccination: With the increase in global travel, there is a growing emphasis on meningococcal vaccination for travellers, particularly to regions where the disease is endemic. This has led to a rise in the demand for vaccines at travel clinics and pharmacies.
Focus on Vaccine Safety and Efficacy: As vaccine safety and efficacy remain paramount, there is a continuous effort to improve existing vaccines and develop new formulations that offer better protection with fewer side effects. This trend is expected to drive innovation in the market.
Meningococcal Vaccines Market Segmentation
Market Breakup by Type
Polysaccharide Vaccines
Conjugate Vaccines
Combination Vaccines
The meningococcal vaccines market is segmented by type into polysaccharide vaccines, conjugate vaccines, and combination vaccines. Polysaccharide vaccines have been traditionally used but are gradually being replaced by conjugate vaccines, which offer longer-lasting protection and are effective in younger populations. Combination vaccines, which protect against multiple diseases, are also gaining traction as they offer broader immunisation coverage with fewer injections.
Market Breakup by Age Group
Infants (0 to 2 years)
Children and Adults (2 Years & Above)
The market is segmented by age group into infants (0 to 2 years) and children and adults (2 years and above). Infants represent a critical target group due to their high vulnerability to meningococcal infections. Vaccination in children and adults is also essential, particularly in regions with high disease prevalence or in populations with increased risk factors.
Market Breakup by Serotype
Serotype A
Serotype B
Serotype C
Serotype W-135
Serotype Y
The market is divided by serotype into serotype A, B, C, W-135, and Y. Serotype B is particularly prevalent in many regions and has been a focus of vaccine development. The availability of vaccines covering multiple serotypes, such as quadrivalent vaccines, is driving the market as they provide broad protection against different strains of the bacterium.
Market Breakup by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Others
The distribution channels for meningococcal vaccines include retail pharmacies, hospital pharmacies, and others. Retail pharmacies are becoming an increasingly popular point of access for vaccines, particularly in developed markets. Hospital pharmacies remain critical for distributing vaccines as part of routine immunisation and outbreak response. Other channels include public health clinics and travel vaccination centres.
Market Breakup by Region
United States
EU-4 and the United Kingdom
Germany
France
Italy
Spain
United Kingdom
Japan
India
Geographically, the meningococcal vaccines market is segmented into the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, and the United Kingdom), Japan, and India. The United States and Europe lead the market due to established immunisation programmes and high awareness levels. Japan and India are emerging markets with growing demand driven by increased government focus on public health and rising vaccination rates.
Meningococcal Vaccines Market Competitive Landscape
The global meningococcal vaccines market is highly competitive, with key players including Incepta Pharmaceuticals Ltd., Bio Med Health Care Products Private Limited, Serum Institute of India Pvt. Ltd., Sanofi S.A., GSK plc, Walvax Biotechnology Co. Ltd., Novartis AG, Hualan Biological Engineering Inc., Pfizer Inc., and Merck & Co., Inc. These companies are focused on expanding their product offerings, enhancing vaccine efficacy, and increasing market penetration through strategic partnerships, mergers, and acquisitions. Companies like Sanofi and GSK are well-known for their extensive vaccine portfolios and global reach, while emerging players like Walvax Biotechnology are gaining ground in key markets, particularly in Asia. The competitive landscape is shaped by ongoing research and development efforts, regulatory approvals, and the ability to meet global demand, particularly in underserved regions.
Key Questions Answered in the Report
What are the primary drivers contributing to the growth of the global meningococcal vaccines market?
How does the increasing awareness of meningococcal disease influence vaccine demand?
What impact do government immunisation programmes have on the market's expansion?
How are technological advancements in vaccine development shaping the meningococcal vaccines market?
What are the major challenges faced by manufacturers in navigating complex regulatory environments?
How does vaccine hesitancy affect vaccination rates and market growth?
What opportunities exist for the development of new vaccines covering additional serotypes?
How are public-private partnerships enhancing vaccine accessibility in low-income regions?
Which regions are expected to see the highest growth in the meningococcal vaccines market?
What are the latest trends in the use of quadrivalent vaccines in routine immunisation programmes?
How is the focus on adult vaccination expanding the meningococcal vaccines market?
What role do retail pharmacies play in the distribution of meningococcal vaccines in developed markets?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the meningococcal vaccines market from 201724-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the meningococcal vaccines market.
The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyse the level of competition within the meningococcal vaccines industry and its attractiveness.
The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market. *Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Meningococcal Vaccines Market Overview: 8 Major Markets
- 3.1 Meningococcal Vaccines Market Historical Value (2017-2023)
- 3.2 Meningococcal Vaccines Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Meningococcal Vaccines: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Meningococcal Vaccines Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2017-2032)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.3.1 Germany
- 7.1.1.3.2 France
- 7.1.1.3.3 Italy
- 7.1.1.3.4 Spain
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.3.1 Germany
- 7.1.2.3.2 France
- 7.1.2.3.3 Italy
- 7.1.2.3.4 Spain
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.3.1 Germany
- 7.1.3.3.2 France
- 7.1.3.3.3 Italy
- 7.1.3.3.4 Spain
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Meningococcal Vaccines Market Landscape: 8 Major Markets*
- 8.1 Meningococcal Vaccines Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Meningococcal Vaccines Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Drug Class
- 8.2.3 Analysis by Route of Administration
- 9 Meningococcal Vaccines Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 8MM Meningococcal Vaccines Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Meningococcal Vaccines Market Segmentation: 8 Major Markets
- 12.1 Meningococcal Vaccines Market by Type
- 12.1.1 Market Overview
- 12.1.2 Polysaccharide Vaccines
- 12.1.3 Conjugate Vaccines
- 12.1.4 Combination Vaccines
- 12.2 Meningococcal Vaccines Market by Age Group
- 12.2.1 Market Overview
- 12.2.2 Infants (0 to 2 years)
- 12.2.3 Children and Adults (2 Years & Above)
- 12.3 Meningococcal Vaccines Market by Serotype
- 12.3.1 Market Overview
- 12.3.2 Serotype A
- 12.3.3 Serotype B
- 12.3.4 Serotype C
- 12.3.5 Serotype W-135
- 12.3.6 Serotype Y
- 12.4 Meningococcal Vaccines Market by Distribution Channel
- 12.4.1 Market Overview
- 12.4.2 Retail Pharmacies
- 12.4.3 Hospital Pharmacies
- 12.4.4 Others
- 12.5 Meningococcal Vaccines Market by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Meningococcal Vaccines Market (2017-2032)
- 13.1 United States Meningococcal Vaccines Market Historical Value (2017-2023)
- 13.2 United States Meningococcal Vaccines Market Forecast Value (2024-2032)
- 13.3 United States Meningococcal Vaccines Market by Type
- 13.3.1 Market Overview
- 13.3.2 Polysaccharide Vaccines
- 13.3.3 Conjugate Vaccines
- 13.3.4 Combination Vaccines
- 13.4 United States Meningococcal Vaccines Market by Age Group
- 13.4.1 Market Overview
- 13.4.2 Infants (0 to 2 years)
- 13.4.3 Children and Adults (2 Years & Above)
- 13.5 United States Meningococcal Vaccines Market by Serotype
- 13.5.1 Market Overview
- 13.5.2 Serotype A
- 13.5.3 Serotype B
- 13.5.4 Serotype C
- 13.5.5 Serotype W-135
- 13.5.6 Serotype Y
- 13.6 United States Meningococcal Vaccines Market by Distribution Channel
- 13.6.1 Market Overview
- 13.6.2 Retail Pharmacies
- 13.6.3 Hospital Pharmacies
- 13.6.4 Others
- 14 EU-4 and United Kingdom Meningococcal Vaccines Market (2017-2032)
- 14.1 EU-4 and United Kingdom Meningococcal Vaccines Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Meningococcal Vaccines Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Meningococcal Vaccines Market by Type
- 14.3.1 Market Overview
- 14.3.2 Polysaccharide Vaccines
- 14.3.3 Conjugate Vaccines
- 14.3.4 Combination Vaccines
- 14.4 EU-4 and United Kingdom Meningococcal Vaccines Market by Age Group
- 14.4.1 Market Overview
- 14.4.2 Infants (0 to 2 years)
- 14.4.3 Children and Adults (2 Years & Above)
- 14.5 EU-4 and United Kingdom Meningococcal Vaccines Market by Serotype
- 14.5.1 Market Overview
- 14.5.2 Serotype A
- 14.5.3 Serotype B
- 14.5.4 Serotype C
- 14.5.5 Serotype W-135
- 14.5.6 Serotype Y
- 14.6 EU-4 and United Kingdom Meningococcal Vaccines Market by Distribution Channel
- 14.6.1 Market Overview
- 14.6.2 Retail Pharmacies
- 14.6.3 Hospital Pharmacies
- 14.6.4 Others
- 15 Japan Meningococcal Vaccines Market
- 15.1 Japan Meningococcal Vaccines Market Historical Value (2017-2023)
- 15.2 Japan Meningococcal Vaccines Market Forecast Value (2024-2032)
- 15.3 Japan Meningococcal Vaccines Market by Type
- 15.3.1 Market Overview
- 15.3.2 Polysaccharide Vaccines
- 15.3.3 Conjugate Vaccines
- 15.3.4 Combination Vaccines
- 15.4 Japan Meningococcal Vaccines Market by Treatment
- 15.4.1 Market Overview
- 15.4.2 Infants (0 to 2 years)
- 15.4.3 Children and Adults (2 Years & Above)
- 15.5 Japan Meningococcal Vaccines Market by Serotype
- 15.5.1 Market Overview
- 15.5.2 Serotype A
- 15.5.3 Serotype B
- 15.5.4 Serotype C
- 15.5.5 Serotype W-135
- 15.5.6 Serotype Y
- 15.6 Japan Meningococcal Vaccines Market by Distribution Channel
- 15.6.1 Market Overview
- 15.6.2 Retail Pharmacies
- 15.6.3 Hospital Pharmacies
- 15.6.4 Others
- 16 India Meningococcal Vaccines Market
- 16.1 India Meningococcal Vaccines Market (2017-2032) Historical Value (2017-2023)
- 16.2 India Meningococcal Vaccines Market (2017-2032) Forecast Value (2024-2032)
- 16.3 India Meningococcal Vaccines Market by Type
- 16.3.1 Market Overview
- 16.3.2 Polysaccharide Vaccines
- 16.3.3 Conjugate Vaccines
- 16.3.4 Combination Vaccines
- 16.4 India Meningococcal Vaccines Market by Treatment
- 16.4.1 Market Overview
- 16.4.2 Infants (0 to 2 years)
- 16.4.3 Children and Adults (2 Years & Above)
- 16.5 India Meningococcal Vaccines Market by Serotype
- 16.5.1 Market Overview
- 16.5.2 Serotype A
- 16.5.3 Serotype B
- 16.5.4 Serotype C
- 16.5.5 Serotype W-135
- 16.5.6 Serotype Y
- 16.6 India Meningococcal Vaccines Market by Distribution Channel
- 16.6.1 Market Overview
- 16.6.2 Retail Pharmacies
- 16.6.3 Hospital Pharmacies
- 16.6.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Strategic Initiatives
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Supplier Landscape
- 22.1 Market Share by Top 5 Companies
- 22.2 Incepta Pharmaceuticals Ltd.
- 22.2.1 Financial Analysis
- 22.2.2 Product Portfolio
- 22.2.3 Demographic Reach and Achievements
- 22.2.4 Mergers and Acquisitions
- 22.2.5 Certifications
- 22.3 Bio Med Health Care Products Private Limited
- 22.3.1 Financial Analysis
- 22.3.2 Product Portfolio
- 22.3.3 Demographic Reach and Achievements
- 22.3.4 Mergers and Acquisitions
- 22.3.5 Certifications
- 22.4 Serum Institute of India Pvt. Ltd .
- 22.4.1 Financial Analysis
- 22.4.2 Product Portfolio
- 22.4.3 Demographic Reach and Achievements
- 22.4.4 Mergers and Acquisitions
- 22.4.5 Certifications
- 22.5 Sanofi S.A .
- 22.5.1 Financial Analysis
- 22.5.2 Product Portfolio
- 22.5.3 Demographic Reach and Achievements
- 22.5.4 Mergers and Acquisitions
- 22.5.5 Certifications
- 22.6 GSK plc
- 22.6.1 Financial Analysis
- 22.6.2 Product Portfolio
- 22.6.3 Demographic Reach and Achievements
- 22.6.4 Mergers and Acquisitions
- 22.6.5 Certifications
- 22.7 Walvax Biotechnology Co . Ltd.
- 22.7.1 Financial Analysis
- 22.7.2 Product Portfolio
- 22.7.3 Demographic Reach and Achievements
- 22.7.4 Mergers and Acquisitions
- 22.7.5 Certifications
- 22.8 Novartis AG
- 22.8.1 Financial Analysis
- 22.8.2 Product Portfolio
- 22.8.3 Demographic Reach and Achievements
- 22.8.4 Mergers and Acquisitions
- 22.8.5 Certifications
- 22.9 Hualan Biological Engineering Inc.
- 22.9.1 Financial Analysis
- 22.9.2 Product Portfolio
- 22.9.3 Demographic Reach and Achievements
- 22.9.4 Mergers and Acquisitions
- 22.9.5 Certifications
- 22.10 Pfizer Inc .
- 22.10.1 Financial Analysis
- 22.10.2 Product Portfolio
- 22.10.3 Demographic Reach and Achievements
- 22.10.4 Mergers and Acquisitions
- 22.10.5 Certifications
- 22.11 Merck & Co., Inc .
- 22.11.1 Financial Analysis
- 22.11.2 Product Portfolio
- 22.11.3 Demographic Reach and Achievements
- 22.11.4 Mergers and Acquisitions
- 22.11.5 Certifications
- 23 Meningococcal Vaccines Market – Distribution Model (Additional Insight)
- 23.1 Overview
- 23.2 Potential Distributors
- 23.3 Key Parameters for Distribution Partner Assessment
- 24 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.